Imugene's porcine patent protected until 2021 in USA

Perth biotechnology company Imugene Ltd has received notice of grant for patent protection for its Porcine Adenoviral Delivery Vector technology in the United States of America, the company has announced.

In addition Imugene has been granted a 295 day extension in the life of the patent in recognition of time lost during the interference defense process. This extension means the patent will now expire in late 2021 in the USA.

The full text of a company announcement is pasted below

Imugene (ASX: IMU) has received notice of grant for patent protection for its Porcine Adenoviral Delivery Vector technology in the US. The Porcine Adenoviral Delivery Vector is the base technology behind all Imugene's pig vaccines. This notice of grant follows the successful defense of the patent interference proceedings in the US which was finalised late last year.

In addition Imugene has been granted a 295 day extension in the life of the patent in recognition of time lost during the interference defense process. This extension means the patent will now expire in late 2021 in the US.

Imugene will now have patent protection for the Porcine Adenoviral Delivery Vector technology in both Europe and the US, in addition to other major pig producing countries around the world. The granting of this important patent will provide Imugene with protection in the world's highest volume and value pig product markets.